Pregabalin - Revision history

MDElliottMD: parser-claude: Pregabalin MedTemplate refill, Top 300 stub upgrade

2026-05-23T06:49:33Z

parser-claude: Pregabalin MedTemplate refill, Top 300 stub upgrade

← Older revision		Revision as of 06:49, 23 May 2026
Line 1:		Line 1:
	{{MedTemplate		{{MedTemplate
	\| generic = Pregabalin		\| generic = Pregabalin
	\| brand = Lyrica		\| brand = Lyrica (IR), Lyrica CR
	\| structure =		\| structure =
	\| classes = Gabapentinoid, Anticonvulsant		\| classes = [[:Category:Gabapentinoids\|Gabapentinoid]], [[:Category:Anticonvulsants\|Anticonvulsant]], [[:Category:Neuropathic pain medicines\|Neuropathic pain medicine]], [[:Category:Schedule V controlled substances\|Schedule V controlled substance]]
	\| ~~mechanism~~ = ~~Alpha~~-2-~~delta voltage~~-~~gated calcium channel ligand~~		\| uses = <vote slug="postherpetic-neuralgia-use">Postherpetic neuralgia (FDA)</vote>, <vote slug="diabetic-peripheral-neuropathy-use">Diabetic peripheral neuropathy (FDA)</vote>, <vote slug="fibromyalgia-pregabalin-use">Fibromyalgia (FDA; the only gabapentinoid with FDA approval for this indication)</vote>, <vote slug="partial-seizures-adjunct-use">Partial-onset seizures (FDA, adjunct)</vote>, <vote slug="sci-neuropathic-pain-use">Spinal-cord-injury neuropathic pain (FDA)</vote>, <vote slug="generalized-anxiety-disorder-use">Generalized anxiety disorder (EU approval; off-label in US)</vote>, <vote slug="social-anxiety-disorder-use">Social anxiety disorder (EU; off-label in US)</vote>
	\| ~~uses~~ =		\| starting_dose = Neuropathic pain: 75 mg PO BID, titrate to 150 mg BID after 1 week. Fibromyalgia: 75 mg PO BID, titrate to 150 mg BID. Anxiety (off-label): 75-150 mg/day divided BID-TID
	\| ~~starting_dose~~ =		\| preparations = Capsules 25, 50, 75, 100, 150, 200, 225, 300 mg; oral solution 20 mg/mL; Lyrica CR tablets 82.5, 165, 330 mg
	\| ~~preparations~~ =		\| fda_max = 600 mg/day (seizures); 450 mg/day (fibromyalgia and neuropathic pain)
	\| ~~fda_max~~ =		\| pill_id =
	\| routes =		\| routes = Oral
	\| onset =		\| onset = Neuropathic pain and fibromyalgia effect emerges over 1-2 weeks
	\| duration =		\| duration = BID-TID dosing for IR; once-daily for CR
	\| halflife =		\| halflife = 6.3 hours<ref name="lyrica-label">FDA Prescribing Information, Lyrica (pregabalin), Pfizer, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021446s035,022488s013lbl.pdf</ref>
	~~\| bioavailability =~~		\| bioavailability = ≥90% (linear pharmacokinetics, distinguishing it favorably from gabapentin's saturable LAT-1 absorption)<ref name="lyrica-label" />
	~~\| pregnancy~~ =		\| pregnancy = Some signal for major congenital malformations; limited human data.{{citation needed}}
	~~\| legal~~ =		\| legal = '''[[USLegal:Schedule V\|Schedule V controlled substance]] in US (federally)''', distinct from gabapentin which remains federally unscheduled<ref name="lyrica-label" />
	\| ~~intro~~ =		\| mechanism = <vote slug="pregabalin-mech-claim">Binds the α2δ-1 auxiliary subunit of voltage-gated calcium channels with approximately 6-fold higher affinity than gabapentin, reducing presynaptic Ca²⁺ influx and excitatory neurotransmitter release (glutamate, substance P, norepinephrine, calcitonin gene-related peptide). Despite the gabapentinoid class name, pregabalin does '''not''' bind GABA receptors or affect GABA reuptake.</vote> Linear pharmacokinetics across the dosing range with non-saturable transport, in sharp contrast to gabapentin where bioavailability falls steeply with dose. Renally eliminated essentially unchanged; dose adjustment required in renal impairment<ref name="lyrica-label" />.
	\| pharmacokinetics =
	\| ~~pharmacodynamics~~ =
	\| ~~indications =~~
	~~\| dosing~~ =
	\| ~~effects~~ =
	~~\| interactions = <pharmaInteractions~~/>
	\| ~~pregnancy_details =~~
	~~\| monitoring~~ =
	~~\| counseling~~ =
	~~\| anecdotes =~~
	~~\| seealso =~~
	~~\| references~~ =
	}}		}}

	[[Category:~~GABAergics~~]]		== References ==
	[[Category:~~Sedative-hypnotics~~]]		<references />
	[[Category:~~Calcium channel blockers (T-type or N/P/Q-type)~~]]
	[[Category:~~Antiepileptics~~]]		[[Category:Gabapentinoids]]
			[[Category:Anticonvulsants]]
			[[Category:Neuropathic pain medicines]]
			[[Category:Schedule V controlled substances]]

MDElliottMD: Category taxonomy ship: retag Anticonvulsants -> Antiepileptics, Sedative-Hypnotics -> Sedative-hypnotics

2026-05-22T00:37:19Z

Category taxonomy ship: retag Anticonvulsants -> Antiepileptics, Sedative-Hypnotics -> Sedative-hypnotics

← Older revision		Revision as of 00:37, 22 May 2026
Line 32:		Line 32:

	[[Category:GABAergics]]		[[Category:GABAergics]]
	[[Category:Sedative-~~Hypnotics~~]]		[[Category:Sedative-hypnotics]]
	[[Category:Calcium channel blockers (T-type or N/P/Q-type)]]		[[Category:Calcium channel blockers (T-type or N/P/Q-type)]]
	[[Category:~~Anticonvulsants~~]]		[[Category:Antiepileptics]]

MDElliottMD: Dedupe migration per interface-claude 2026-05-20: Anticonvulsants / Antiepileptics merged into canonical Anticonvulsants. Member retagged.

2026-05-19T18:00:15Z

Dedupe migration per interface-claude 2026-05-20: Anticonvulsants / Antiepileptics merged into canonical Anticonvulsants. Member retagged.

← Older revision		Revision as of 18:00, 19 May 2026
Line 30:		Line 30:
	\| references =		\| references =
	}}		}}


	[[Category:GABAergics]]		[[Category:GABAergics]]
	[[Category:Sedative-Hypnotics]]		[[Category:Sedative-Hypnotics]]
	[[Category:Calcium channel blockers (T-type or N/P/Q-type)]]		[[Category:Calcium channel blockers (T-type or N/P/Q-type)]]
	[[Category:Anticonvulsants ~~/ Antiepileptics~~]]		[[Category:Anticonvulsants]]

MDElliottMD: Remove Category:Psychostimulants tag (not a psychostimulant — sedative/anxiolytic/anticonvulsant/non-stimulant carryover from Stimulants & Wake-Promoting Agents rename)

2026-05-18T00:48:11Z

Remove Category:Psychostimulants tag (not a psychostimulant — sedative/anxiolytic/anticonvulsant/non-stimulant carryover from Stimulants & Wake-Promoting Agents rename)

← Older revision		Revision as of 00:48, 18 May 2026
Line 32:		Line 32:


	~~[[Category:Psychostimulants]]~~
	[[Category:GABAergics]]		[[Category:GABAergics]]
	[[Category:Sedative-Hypnotics]]		[[Category:Sedative-Hypnotics]]
	[[Category:Calcium channel blockers (T-type or N/P/Q-type)]]		[[Category:Calcium channel blockers (T-type or N/P/Q-type)]]
	[[Category:Anticonvulsants / Antiepileptics]]		[[Category:Anticonvulsants / Antiepileptics]]

MDElliottMD: Recategorize: Stimulants -> Psychostimulants

2026-05-17T10:51:02Z

Recategorize: Stimulants -> Psychostimulants

← Older revision		Revision as of 10:51, 17 May 2026
Line 32:		Line 32:


	[[Category:~~Stimulants~~]]		[[Category:Psychostimulants]]
	[[Category:GABAergics]]		[[Category:GABAergics]]
	[[Category:Sedative-Hypnotics]]		[[Category:Sedative-Hypnotics]]
	[[Category:Calcium channel blockers (T-type or N/P/Q-type)]]		[[Category:Calcium channel blockers (T-type or N/P/Q-type)]]
	[[Category:Anticonvulsants / Antiepileptics]]		[[Category:Anticonvulsants / Antiepileptics]]

MDElliottMD: Recategorize: Stimulants & Wake-Promoting Agents -> Stimulants

2026-05-17T10:45:15Z

Recategorize: Stimulants & Wake-Promoting Agents -> Stimulants

← Older revision		Revision as of 10:45, 17 May 2026
Line 32:		Line 32:


	[[Category:Stimulants ~~& Wake-Promoting Agents~~]]		[[Category:Stimulants]]
	[[Category:GABAergics]]		[[Category:GABAergics]]
	[[Category:Sedative-Hypnotics]]		[[Category:Sedative-Hypnotics]]
	[[Category:Calcium channel blockers (T-type or N/P/Q-type)]]		[[Category:Calcium channel blockers (T-type or N/P/Q-type)]]
	[[Category:Anticonvulsants / Antiepileptics]]		[[Category:Anticonvulsants / Antiepileptics]]

MDElliottMD: Comprehensive categorization: +Calcium channel blockers (T-type or N/P/Q-type), Anticonvulsants / Antiepileptics

2026-05-15T18:42:20Z

Comprehensive categorization: +Calcium channel blockers (T-type or N/P/Q-type), Anticonvulsants / Antiepileptics

← Older revision		Revision as of 18:42, 15 May 2026
Line 35:		Line 35:
	[[Category:GABAergics]]		[[Category:GABAergics]]
	[[Category:Sedative-Hypnotics]]		[[Category:Sedative-Hypnotics]]
			[[Category:Calcium channel blockers (T-type or N/P/Q-type)]]
			[[Category:Anticonvulsants / Antiepileptics]]

MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines

2026-05-14T15:06:58Z

Assign pharmacological categories from List_of_CNS-active_medicines

← Older revision		Revision as of 15:06, 14 May 2026
Line 31:		Line 31:
	}}		}}


			[[Category:Stimulants & Wake-Promoting Agents]]
			[[Category:GABAergics]]
	[[Category:Sedative-Hypnotics]]		[[Category:Sedative-Hypnotics]]

MDElliottMD: Pharmacopedia: add

2026-05-14T03:31:06Z

Pharmacopedia: add <pharmaInteractions/>

← Older revision		Revision as of 03:31, 14 May 2026
Line 22:		Line 22:
	\| dosing =		\| dosing =
	\| effects =		\| effects =
	\| interactions =		\| interactions = <pharmaInteractions/>
	\| pregnancy_details =		\| pregnancy_details =
	\| monitoring =		\| monitoring =

MDElliottMD: Pharmacopedia: remove contraindications parameter

2026-05-14T02:40:47Z

Pharmacopedia: remove contraindications parameter

← Older revision		Revision as of 02:40, 14 May 2026
Line 22:		Line 22:
	\| dosing =		\| dosing =
	\| effects =		\| effects =
	~~\| contraindications =~~
	\| interactions =		\| interactions =
	\| pregnancy_details =		\| pregnancy_details =